# T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

> **NCT02280811** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Vaginal Cancer
- Cervical Cancer
- Anal Cancer
- Penile Cancer
- Oropharyngeal Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** E6 TCR
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT02280811
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-14
- **Primary completion:** 2016-06-28
- **Final completion:** 2016-06-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280811, "T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02280811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*